Linked Life Data

8508427

Source:http://linkedlifedata.com/resource/pubmed/id/8508427

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1993-7-13
pubmed:abstractText
In an attempt to decrease the toxic effects of fluorouracil, doxorubicin, and methotrexate (FAMTX) by reducing the dose of methotrexate from 1500 mg/m2, according to the original regimen, to 1000 mg/m2, the authors designed the modified FAMTX treatment that was evaluated in a prospective Phase II-III randomized trial.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0008-543X
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
72
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
37-41
pubmed:dateRevised
2010-3-24
pubmed:meshHeading
pubmed:year
1993
pubmed:articleTitle
Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer.
pubmed:affiliation
Division of Hematology/Oncology, Hospital das Clinicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial, Clinical Trial, Phase II, Clinical Trial, Phase III